Loading…

Design and synthesis of 3-phenyl tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands

Tetrahydronaphthalenic analogues of melatonin have been synthesized and evaluated as melatonin receptor ligands. Introduction of a phenyl substituent in the 3-position of the tetraline ring allows to obtain MT(2) selective ligands. Activity and MT(2) selectivity can be modulated with suitable modifi...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry 2003-03, Vol.11 (5), p.753-759
Main Authors: YOUS, Saïd, DURIEUX-POISSONNIER, Sophie, LESIEUR, Daniel, LIPKA-BELLOLI, Emmanuelle, GUELZIM, Halim, BOCHU, Christophe, AUDINOT, Valérie, BOUTIN, Jean A, DELAGRANGE, Philippe, BENNEJEAN, Caroline, RENARD, Pierre
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c335t-80b8bc5af2cfc45f0bd1eddcf2458574b10dfbd1c47adfbc01c6f921a52991a53
cites cdi_FETCH-LOGICAL-c335t-80b8bc5af2cfc45f0bd1eddcf2458574b10dfbd1c47adfbc01c6f921a52991a53
container_end_page 759
container_issue 5
container_start_page 753
container_title Bioorganic & medicinal chemistry
container_volume 11
creator YOUS, Saïd
DURIEUX-POISSONNIER, Sophie
LESIEUR, Daniel
LIPKA-BELLOLI, Emmanuelle
GUELZIM, Halim
BOCHU, Christophe
AUDINOT, Valérie
BOUTIN, Jean A
DELAGRANGE, Philippe
BENNEJEAN, Caroline
RENARD, Pierre
description Tetrahydronaphthalenic analogues of melatonin have been synthesized and evaluated as melatonin receptor ligands. Introduction of a phenyl substituent in the 3-position of the tetraline ring allows to obtain MT(2) selective ligands. Activity and MT(2) selectivity can be modulated with suitable modifications of the N-acyl substituent. The (+)-(RR)-cis enantiomer of the N-[2-(7-methoxy-3-phenyl-1,2,3,4-tetrahydro-naphthalen-1-yl)ethyl]cyclobutyl carboxamide (14) is one of the most MT(2) selective ligands described until now and behaves as an antagonist.
doi_str_mv 10.1016/S0968-0896(02)00473-X
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72979023</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72979023</sourcerecordid><originalsourceid>FETCH-LOGICAL-c335t-80b8bc5af2cfc45f0bd1eddcf2458574b10dfbd1c47adfbc01c6f921a52991a53</originalsourceid><addsrcrecordid>eNpFkE1P3DAQQK2qqGyhPwHkS1F7CIztOImPCNpSCdRDqcTNcpzxxpXX2dpZqv33eGEFl_nSmxnpEXLC4JwBay5-g2q6CjrVfAH-FaBuRfXwjixY3dSVEIq9J4tX5JB8zPkvAPBasQ_kkHEpOgC5INM1Zr-M1MSB5m2cx9JmOjkqqvWIcRvojHMy43ZIUzTrcR5NwOgtHTD5RzP7R8zUZBrxP80Y0O4m9O6e0xUGM0_RR0zLwge_LD_yMTlwJmT8tM9H5M_3b_dXN9Xtrx8_ry5vKyuEnKsO-q630jhuna2lg35gOAzW8Vp2sq17BoMrM1u3phQWmG2c4sxIrlSJ4oicvdxdp-nfBvOsVz5bDMFEnDZZt1y1CrgooHwBbZpyTuj0OvmVSVvNQO9M62fTeqdRA9fPpvVD2TvdP9j0KxzetvZqC_B5D5hsTXDJROvzG9fyrlCdeAIX1Im4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72979023</pqid></control><display><type>article</type><title>Design and synthesis of 3-phenyl tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands</title><source>Elsevier</source><creator>YOUS, Saïd ; DURIEUX-POISSONNIER, Sophie ; LESIEUR, Daniel ; LIPKA-BELLOLI, Emmanuelle ; GUELZIM, Halim ; BOCHU, Christophe ; AUDINOT, Valérie ; BOUTIN, Jean A ; DELAGRANGE, Philippe ; BENNEJEAN, Caroline ; RENARD, Pierre</creator><creatorcontrib>YOUS, Saïd ; DURIEUX-POISSONNIER, Sophie ; LESIEUR, Daniel ; LIPKA-BELLOLI, Emmanuelle ; GUELZIM, Halim ; BOCHU, Christophe ; AUDINOT, Valérie ; BOUTIN, Jean A ; DELAGRANGE, Philippe ; BENNEJEAN, Caroline ; RENARD, Pierre</creatorcontrib><description>Tetrahydronaphthalenic analogues of melatonin have been synthesized and evaluated as melatonin receptor ligands. Introduction of a phenyl substituent in the 3-position of the tetraline ring allows to obtain MT(2) selective ligands. Activity and MT(2) selectivity can be modulated with suitable modifications of the N-acyl substituent. The (+)-(RR)-cis enantiomer of the N-[2-(7-methoxy-3-phenyl-1,2,3,4-tetrahydro-naphthalen-1-yl)ethyl]cyclobutyl carboxamide (14) is one of the most MT(2) selective ligands described until now and behaves as an antagonist.</description><identifier>ISSN: 0968-0896</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/S0968-0896(02)00473-X</identifier><identifier>PMID: 12538005</identifier><language>eng</language><publisher>Oxford: Elsevier Science</publisher><subject>Animals ; Binding, Competitive - drug effects ; Biological and medical sciences ; CHO Cells ; Cricetinae ; Dose-Response Relationship, Drug ; Drug Design ; Guanosine 5'-O-(3-Thiotriphosphate) - metabolism ; Guinea Pigs ; Humans ; Indicators and Reagents ; Ligands ; Magnetic Resonance Spectroscopy ; Medical sciences ; Melatonin - analogs &amp; derivatives ; Melatonin - metabolism ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems ; Pharmacology. Drug treatments ; Receptors, Cell Surface - drug effects ; Receptors, Cytoplasmic and Nuclear - drug effects ; Receptors, Melatonin ; Structure-Activity Relationship ; Tetrahydronaphthalenes - chemical synthesis ; Tetrahydronaphthalenes - pharmacology</subject><ispartof>Bioorganic &amp; medicinal chemistry, 2003-03, Vol.11 (5), p.753-759</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c335t-80b8bc5af2cfc45f0bd1eddcf2458574b10dfbd1c47adfbc01c6f921a52991a53</citedby><cites>FETCH-LOGICAL-c335t-80b8bc5af2cfc45f0bd1eddcf2458574b10dfbd1c47adfbc01c6f921a52991a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17280538$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12538005$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YOUS, Saïd</creatorcontrib><creatorcontrib>DURIEUX-POISSONNIER, Sophie</creatorcontrib><creatorcontrib>LESIEUR, Daniel</creatorcontrib><creatorcontrib>LIPKA-BELLOLI, Emmanuelle</creatorcontrib><creatorcontrib>GUELZIM, Halim</creatorcontrib><creatorcontrib>BOCHU, Christophe</creatorcontrib><creatorcontrib>AUDINOT, Valérie</creatorcontrib><creatorcontrib>BOUTIN, Jean A</creatorcontrib><creatorcontrib>DELAGRANGE, Philippe</creatorcontrib><creatorcontrib>BENNEJEAN, Caroline</creatorcontrib><creatorcontrib>RENARD, Pierre</creatorcontrib><title>Design and synthesis of 3-phenyl tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands</title><title>Bioorganic &amp; medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>Tetrahydronaphthalenic analogues of melatonin have been synthesized and evaluated as melatonin receptor ligands. Introduction of a phenyl substituent in the 3-position of the tetraline ring allows to obtain MT(2) selective ligands. Activity and MT(2) selectivity can be modulated with suitable modifications of the N-acyl substituent. The (+)-(RR)-cis enantiomer of the N-[2-(7-methoxy-3-phenyl-1,2,3,4-tetrahydro-naphthalen-1-yl)ethyl]cyclobutyl carboxamide (14) is one of the most MT(2) selective ligands described until now and behaves as an antagonist.</description><subject>Animals</subject><subject>Binding, Competitive - drug effects</subject><subject>Biological and medical sciences</subject><subject>CHO Cells</subject><subject>Cricetinae</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Design</subject><subject>Guanosine 5'-O-(3-Thiotriphosphate) - metabolism</subject><subject>Guinea Pigs</subject><subject>Humans</subject><subject>Indicators and Reagents</subject><subject>Ligands</subject><subject>Magnetic Resonance Spectroscopy</subject><subject>Medical sciences</subject><subject>Melatonin - analogs &amp; derivatives</subject><subject>Melatonin - metabolism</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, Cell Surface - drug effects</subject><subject>Receptors, Cytoplasmic and Nuclear - drug effects</subject><subject>Receptors, Melatonin</subject><subject>Structure-Activity Relationship</subject><subject>Tetrahydronaphthalenes - chemical synthesis</subject><subject>Tetrahydronaphthalenes - pharmacology</subject><issn>0968-0896</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNpFkE1P3DAQQK2qqGyhPwHkS1F7CIztOImPCNpSCdRDqcTNcpzxxpXX2dpZqv33eGEFl_nSmxnpEXLC4JwBay5-g2q6CjrVfAH-FaBuRfXwjixY3dSVEIq9J4tX5JB8zPkvAPBasQ_kkHEpOgC5INM1Zr-M1MSB5m2cx9JmOjkqqvWIcRvojHMy43ZIUzTrcR5NwOgtHTD5RzP7R8zUZBrxP80Y0O4m9O6e0xUGM0_RR0zLwge_LD_yMTlwJmT8tM9H5M_3b_dXN9Xtrx8_ry5vKyuEnKsO-q630jhuna2lg35gOAzW8Vp2sq17BoMrM1u3phQWmG2c4sxIrlSJ4oicvdxdp-nfBvOsVz5bDMFEnDZZt1y1CrgooHwBbZpyTuj0OvmVSVvNQO9M62fTeqdRA9fPpvVD2TvdP9j0KxzetvZqC_B5D5hsTXDJROvzG9fyrlCdeAIX1Im4</recordid><startdate>20030306</startdate><enddate>20030306</enddate><creator>YOUS, Saïd</creator><creator>DURIEUX-POISSONNIER, Sophie</creator><creator>LESIEUR, Daniel</creator><creator>LIPKA-BELLOLI, Emmanuelle</creator><creator>GUELZIM, Halim</creator><creator>BOCHU, Christophe</creator><creator>AUDINOT, Valérie</creator><creator>BOUTIN, Jean A</creator><creator>DELAGRANGE, Philippe</creator><creator>BENNEJEAN, Caroline</creator><creator>RENARD, Pierre</creator><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030306</creationdate><title>Design and synthesis of 3-phenyl tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands</title><author>YOUS, Saïd ; DURIEUX-POISSONNIER, Sophie ; LESIEUR, Daniel ; LIPKA-BELLOLI, Emmanuelle ; GUELZIM, Halim ; BOCHU, Christophe ; AUDINOT, Valérie ; BOUTIN, Jean A ; DELAGRANGE, Philippe ; BENNEJEAN, Caroline ; RENARD, Pierre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c335t-80b8bc5af2cfc45f0bd1eddcf2458574b10dfbd1c47adfbc01c6f921a52991a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Animals</topic><topic>Binding, Competitive - drug effects</topic><topic>Biological and medical sciences</topic><topic>CHO Cells</topic><topic>Cricetinae</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Design</topic><topic>Guanosine 5'-O-(3-Thiotriphosphate) - metabolism</topic><topic>Guinea Pigs</topic><topic>Humans</topic><topic>Indicators and Reagents</topic><topic>Ligands</topic><topic>Magnetic Resonance Spectroscopy</topic><topic>Medical sciences</topic><topic>Melatonin - analogs &amp; derivatives</topic><topic>Melatonin - metabolism</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, Cell Surface - drug effects</topic><topic>Receptors, Cytoplasmic and Nuclear - drug effects</topic><topic>Receptors, Melatonin</topic><topic>Structure-Activity Relationship</topic><topic>Tetrahydronaphthalenes - chemical synthesis</topic><topic>Tetrahydronaphthalenes - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YOUS, Saïd</creatorcontrib><creatorcontrib>DURIEUX-POISSONNIER, Sophie</creatorcontrib><creatorcontrib>LESIEUR, Daniel</creatorcontrib><creatorcontrib>LIPKA-BELLOLI, Emmanuelle</creatorcontrib><creatorcontrib>GUELZIM, Halim</creatorcontrib><creatorcontrib>BOCHU, Christophe</creatorcontrib><creatorcontrib>AUDINOT, Valérie</creatorcontrib><creatorcontrib>BOUTIN, Jean A</creatorcontrib><creatorcontrib>DELAGRANGE, Philippe</creatorcontrib><creatorcontrib>BENNEJEAN, Caroline</creatorcontrib><creatorcontrib>RENARD, Pierre</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic &amp; medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YOUS, Saïd</au><au>DURIEUX-POISSONNIER, Sophie</au><au>LESIEUR, Daniel</au><au>LIPKA-BELLOLI, Emmanuelle</au><au>GUELZIM, Halim</au><au>BOCHU, Christophe</au><au>AUDINOT, Valérie</au><au>BOUTIN, Jean A</au><au>DELAGRANGE, Philippe</au><au>BENNEJEAN, Caroline</au><au>RENARD, Pierre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design and synthesis of 3-phenyl tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands</atitle><jtitle>Bioorganic &amp; medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>2003-03-06</date><risdate>2003</risdate><volume>11</volume><issue>5</issue><spage>753</spage><epage>759</epage><pages>753-759</pages><issn>0968-0896</issn><eissn>1464-3391</eissn><abstract>Tetrahydronaphthalenic analogues of melatonin have been synthesized and evaluated as melatonin receptor ligands. Introduction of a phenyl substituent in the 3-position of the tetraline ring allows to obtain MT(2) selective ligands. Activity and MT(2) selectivity can be modulated with suitable modifications of the N-acyl substituent. The (+)-(RR)-cis enantiomer of the N-[2-(7-methoxy-3-phenyl-1,2,3,4-tetrahydro-naphthalen-1-yl)ethyl]cyclobutyl carboxamide (14) is one of the most MT(2) selective ligands described until now and behaves as an antagonist.</abstract><cop>Oxford</cop><pub>Elsevier Science</pub><pmid>12538005</pmid><doi>10.1016/S0968-0896(02)00473-X</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0968-0896
ispartof Bioorganic & medicinal chemistry, 2003-03, Vol.11 (5), p.753-759
issn 0968-0896
1464-3391
language eng
recordid cdi_proquest_miscellaneous_72979023
source Elsevier
subjects Animals
Binding, Competitive - drug effects
Biological and medical sciences
CHO Cells
Cricetinae
Dose-Response Relationship, Drug
Drug Design
Guanosine 5'-O-(3-Thiotriphosphate) - metabolism
Guinea Pigs
Humans
Indicators and Reagents
Ligands
Magnetic Resonance Spectroscopy
Medical sciences
Melatonin - analogs & derivatives
Melatonin - metabolism
Neuropharmacology
Neurotransmitters. Neurotransmission. Receptors
Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems
Pharmacology. Drug treatments
Receptors, Cell Surface - drug effects
Receptors, Cytoplasmic and Nuclear - drug effects
Receptors, Melatonin
Structure-Activity Relationship
Tetrahydronaphthalenes - chemical synthesis
Tetrahydronaphthalenes - pharmacology
title Design and synthesis of 3-phenyl tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T08%3A55%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design%20and%20synthesis%20of%203-phenyl%20tetrahydronaphthalenic%20derivatives%20as%20new%20selective%20MT2%20melatoninergic%20ligands&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=YOUS,%20Sa%C3%AFd&rft.date=2003-03-06&rft.volume=11&rft.issue=5&rft.spage=753&rft.epage=759&rft.pages=753-759&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/S0968-0896(02)00473-X&rft_dat=%3Cproquest_cross%3E72979023%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c335t-80b8bc5af2cfc45f0bd1eddcf2458574b10dfbd1c47adfbc01c6f921a52991a53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72979023&rft_id=info:pmid/12538005&rfr_iscdi=true